(Q44925317)

7 December 2017

title

5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy (English)

1 reference

7 December 2017

0 references

1 reference

Gerald M Higa

1

1 reference

7 December 2017

Miklos L Auber

2

1 reference

7 December 2017

Ramin Altaha

3

1 reference

7 December 2017

Debbie Piktel

4

1 reference

7 December 2017

Sohba Kurian

5

1 reference

7 December 2017

Gerry Hobbs

6

1 reference

7 December 2017

Kenneth Landreth

7

1 reference

7 December 2017

publication date

1 December 2006

1 reference

Journal of Oncology Pharmacy Practice

7 December 2017

published in

1 reference

7 December 2017

volume

12

1 reference

7 December 2017

issue

4

1 reference

7 December 2017

page(s)

201-209

1 reference

Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1078155206072080

Serotonin mechanisms in chemotherapy-induced emesis in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206072080

Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206072080

A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206072080

Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206072080

The severity and pattern of emesis following different cytotoxic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206072080

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206072080

Potential of substance P antagonists as antiemetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206072080

Enterochromaffin cells as the endocrine source of gastrointestinal substance P

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206072080

Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206072080

Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206072080

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206072080

Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206072080

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206072080

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206072080

Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206072080

Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206072080

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206072080

Treatment with para-chlorophenylalanine antagonises the emetic response and the serotonin-releasing actions of cisplatin in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206072080

Methodological issues in antiemetic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206072080

Proposal for classifying the acute emetogenicity of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206072080

Substance P radioimmunoassay using Nalpha-tyrosyl-substance P and demonstration of the presence of substance P-like immunoreactivities in human blood and porcine tissue extracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206072080

Plasma chromogranin A: a marker of serotonin release and of emesis associated with cisplatin chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206072080

The relationship between parameters of serotonin metabolism and emetogenic potential of platinum-based chemotherapy regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155206072080

21 January 2018

Identifiers

DOI

10.1177/1078155206072080

1 reference

7 December 2017

1 reference